Vantage Investment Advisors’s DexCom DXCM Stock Holding History

Vantage Investment Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-220	Closed	–	–	793
2016 Q2	$0	Buy	+220	New	+$3.75K	﹤0.01%	857

Other funds holding DXCM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Vantage Investment Advisors's DXCM Position: Q3 2016 in Review

Vantage Investment Advisors sold out of DexCom (DXCM) in Q3 2016, closing a stake of 220 shares.

Vantage Investment Advisors first reported a position in DXCM in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 291 funds tracked by Wall St. Rank hold DXCM as of Q3 2016.

Vantage Investment Advisors reported no remaining DexCom position as of Q3 2016 after selling out during the quarter.
Vantage Investment Advisors sold 220 DexCom shares in Q3 2016.
Vantage Investment Advisors first reported a position in DexCom in Q2 2016 and held it in 1 quarter.
Vantage Investment Advisors's DexCom position peaked at $0 in Q2 2016.
291 funds tracked by Wall St. Rank held DexCom as of Q3 2016.

Based on Vantage Investment Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.